Clinical trials: Standard Therapy
Overactive Bladder Syndrome
Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug
Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug and Its Conelations With Voiding Diary, King's Health Quentionaire…
- Trial name
- NCT01627145
- Testing
- Solifenacin
- Where
- Taiwan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Femoral Artery Stenosis, Popliteal Artery Stenosis
Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM)
The post approval study will enroll US female patients presenting with claudication or ischemic rest pain and an angiographically significant lesion in the superficial femoral or popliteal artery.
- Conditions
- Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion, Popliteal Artery Occlusion
- Trial name
- CONFIRM (NCT02813577)
- Testing
- Lutonix® 035 Drug Coated Balloon PTA Catheter
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- C. R. Bard
Travelers' Diarrhea
Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea
The study will compare durations of diarrhea among subjects who report to clinic for treatment and who receive either: 1. standard rifaximin therapy at a dose of 200 mg three times a day for 3 days, OR 2.
- Trial name
- Rifaximin 600 (NCT00875875)
- Testing
- Rifaximin
- Where
- Mexico
- Sponsor
- The University of Texas Health Science Center, Houston
Parkinson Disease
Utilization of Target Ranges to Treat Persons With Parkinson's Disease by Objective Measurement Using the PKG
The main objective of this study is to evaluate whether persons with Parkinson's disease (PwP) whose Parkinson's disease (PD) symptoms are uncontrolled have improved clinical patient outcomes and quality of life when managed with…
- Trial name
- TARGET-PwP (NCT04381065)
- Testing
- Personal KinetiGraph® (PKG®) System, Personal KinetiGraph® (PKG®) Watch
- Sponsor
- Global Kinetics Corporation
Helicobacter Pylori Infection
Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients
This exploratory study is designed to compare safety and efficacy between a Tegoprazan dose-specific standard triple therapy and Lansoprazole standard triple therapy in H. pylori positive patients.
- Trial name
- NCT05933031
- Testing
- Tegoprazan 50 mg Triple Therapy, Tegoprazan 100 mg Triple Therapy, Lansoprazole Triple Therapy
- Where
- South Korea
- Volunteers
- 381 people
- Sponsor
- HK inno.N Corporation
Advanced Colorectal Carcinoma
Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer
A randomized, controlled phase II clinical trial of Fruquintinib combined with Raltitrexed versus Fruquintinib monotherapy in patients with advanced colorectal cancer who had failed second-line or above standard chemotherapy
- Trial name
- NCT04582981
- Testing
- Fruquintinib and raltitrexed, Fruquintinib
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Fudan University
Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
This phase I trial studies the side effects and best dose of berzosertib (M6620 [VX-970]) when given together with whole brain radiation therapy in treating patients with non-small cell lung cancer, small cell lung cancer, or…
- Conditions
- Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT02589522
- Testing
- Berzosertib, Quality-of-Life Assessment, Therapeutic Conventional Surgery
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Acute Cardiogenic Pulmonary Edema
OUT-OF-HOSPITAL CPAP STUDY
Evaluate efficacy and safety of CPAP in a randomised standard treatment controlled study, in out-of-hospital patients with acute cardiogenic pulmonary edema.
- Trial name
- NCT00439075
- Testing
- CPAP, standard treatment
- Where
- France
- Volunteers
- 124 people
- Sponsor
- University Hospital, Toulouse
Ventilator Associated Pneumonia, Lower Respiratory Infection
Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia
To investigate the pharmacokinetic characteristics of POL7080 co-administered with SoC during 10 to 14 days of treatment in VAP patients due to suspected or documented Pseudomonas aeruginosa infection
- Trial name
- NCT02096328
- Testing
- POL7080
- Where
- 10 sites in Greece, Spain
- Volunteers
- 25 people
- Sponsor
- Polyphor Ltd.
Surgical Resection of Superficial Renal Tumour
TachoComb S Versus Standard Surgical Treatment in Surgical Resection of Renal Tumour (TC-015-IN)
The overall objective is to compare efficacy and safety of TachoComb S and standard surgical treatment for the control of local bleeding in patients undergoing surgical resection of renal tumours.
- Trial name
- NCT00241163
- Testing
- Fibrinogen (human) + thrombin (human) (TachoSil)
- Where
- Denmark
- Volunteers
- 170 people
- Sponsor
- Takeda
Asthma
An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma
This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) or 200mcg Fluticasone Furoate…
- Trial name
- NCT01706198
- Testing
- fluticasone furoate + vilanterol, inhaled corticosteroid with or without a long acting beta2-agonist
- Where
- 180 sites in United Kingdom
- Volunteers
- 4,233 people
- Sponsor
- GlaxoSmithKline
Thoracic Solid Malignant Tumor
Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
To evaluate the safety and efficacy of Boron Neutron Capture Therapy (BNCT) in patients with recurrent thoracic solid tumors that are difficult to treat with standard radiation therapy or drug therapy and are unresectable.
- Trial name
- NCT06603987
- Testing
- BNCT, ［18F］FBPA
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Stella Pharma Corporation
Sickle Cell Anemia
Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea
The primary goal of the Phase III TWiTCH trial is to compare 24 months of alternative therapy (hydroxyurea) to standard therapy (transfusions) for pediatric subjects with sickle cell anemia and abnormally high (≥200 cm/sec)…
- Trial name
- TWiTCH (NCT01425307)
- Testing
- Hydroxyurea
- Volunteers
- 159 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cirrhosis, Liver
Transitional Care Program for Fluid Overload in Cirrhosis
The goal of this clinical trial is to learn about an intensive monitoring plan (transitional care program) in patients with cirrhosis and excessive swelling that are going to be discharged from the hospital.
- Trial name
- NCT06174272
- Testing
- Transitional Care Program
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Malignant Glioma, Glioblastoma Multiforme
Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
The purpose of this study was to evaluate the safety and potential efficacy of CAN-2409 (also known / previously described as AdV-tk, GMCI) for malignant gliomas.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
- Trial name
- BrTK02 (NCT00589875)
- Testing
- CAN-2409, Valacyclovir, Temozolomide
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Candel Therapeutics, Inc.
Type 1 Diabetes
Fast Advanced Closed-Loop Therapy
A double-blind, multinational, multicenter, randomised, 2-period crossover study to assess the efficacy and safety of advanced closed-loop insulin delivery with Minimed 670G 4.0 system comparing Faster Insulin Aspart to Standard…
- Trial name
- FACT (NCT04853030)
- Testing
- Fiasp, Novorapid
- Where
- 2 sites in Austria, Slovenia
- Volunteers
- 30 people
- Sponsor
- University of Ljubljana, Faculty of Medicine
Periodontal Disease
Periodontal Follow-up and Glycemy in Patients With Type 2 Diabetes
Diabetes is a disease in which the majority of these patients have type 2 diabetes, linked to poor use of insulin by the body. Periodontitis is a chronic disease characterized by an immuno-inflammatory reaction with local…
- Trial name
- GlyCoSup (NCT07165171)
- Testing
- Innovative periodontal monitoring (SuP innovative)
- Where
- 8 sites in France
- Volunteers
- 516 people
- Sponsor
- Hospices Civils de Lyon
Trauma, Injuries
Improving Family-Centered Pediatric Trauma Care: The Standard of Care Versus the Virtual Pediatric Trauma Center
More than 41 million children, or 55 percent of all children in the United States, live more than 30 minutes away from a pediatric trauma center.
- Trial name
- NCT04469036
- Testing
- Virtual Pediatric Trauma Center
- Where
- United States
- Volunteers
- 595 people
- Sponsor
- University of California, Davis
B-cell Acute Lymphoblastic Leukemia
Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
This is a single-center, open-label, single-arm prospective study designed to evaluate the safety, tolerability, and efficacy of dual-target CD22/CD19 chimeric antigen receptor (CAR)-T cell therapy as consolidation treatment in…
- Trial name
- NCT07575919
- Testing
- CD22/CD19 Dual-Target CAR-T Cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Liping Dou
Atherosclerosis, Percutaneous Coronary Intervention
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
The study is designed to compare the efficacy and safety profile of cangrelor to standard of care in patients require percutaneous coronary intervention (PCI).
- Conditions
- Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- CHAMPION (NCT01156571)
- Testing
- cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor
- Where
- United States
- Volunteers
- 11,145 people
- Sponsor
- The Medicines Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.